CliffBio
small molecule

POSLUMA

FLOTUFOLASTAT F-18 GALLIUM

Loss of exclusivityNovember 2041latest FDA-listed patent expiry
CompanyBLUE EARTH DIAGNOSTICS LTD

Drug detail

Brand namePOSLUMA
Active ingredientFLOTUFOLASTAT F-18 GALLIUM
Strength25ML (8-158mCi/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2023
Marketing statusRX

Listed patents

PatentExpiresType
12036290November 2041product
12427207November 2041product
11413360November 2038substance
12357711November 2038substance
12377176November 2038substance
12390540August 2038substance

Regulatory exclusivity

CodeExpires
NCEMay 2028

More from BLUE EARTH DIAGNOSTICS LTD

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.